Does early olaparib administration improve prognosis in patients with
HER2-negative metastatic breast cancer and BRCA1 and/or BRCA2 pathogenic
variants?: Finding from four cases
We herein describe our experience of four patients who had been
diagnosed as metastatic breast cancer with BRCA 1/2 pathogenic variants.
Prior anthracycline and/or taxane-based therapies needed before
administration of PARP inhibitors might be still controversial in terms
of patients benefit.